MicroRNA-587 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Targeting Ribosomal Protein SA

Table 1

Relationship between miR-587/RPSA expressions and clinicopathologic features of HCC patients.

Clinicopathological	miR-587			Patients	RPSA			Patients
	Low	High	value		Low	High	value
Features
Gender			0.534				0.132
Female	7	5		12	9	4		13
Male	36	38		74	34	39		73
Age(years)			0.245				0.357
≤55	32	27		59	27	31		58
>55	11	16		27	16	12		28
Smoking status			0.808				0.194
Negative	31	32		64	36	31		67
Positive	12	11		22	7	12		19
Alcoholism			0.795				0.047
Negative	34	33		67	39	32		71
Positive	9	10		19	4	11		15
Size (cm)			0.223				0.194
≤5	14	9		23	12	7		19
>5	29	34		63	31	36		67
Number			0.645				0.516
≤2	28	30		58	22	25		47
>2	15	13		28	21	18		39
HBV			0.802				0.336
Negative	11	10		21	10	14		24
Positive	32	33		65	33	29		62
AFP (ng/ml)			0.002				0.272
≤400	25	11		35	20	15		35
>400	18	32		51	23	28		51
Liver cirrhosis			0.058				0.534
No	5	12		17	7	5		12
Yes	38	31		69	36	38		74
Ascites			0.725				0.501
No	39	38		77	37	39		76
Yes	4	5		9	6	4		10
BCLC stage			0.828				0.387
0 + A	24	25		48	22	18		40
B + C	19	18		38	21	25		46
TNM stage			0.996				0.308
I-II	21	20		41	22	16		38
III-IV	22	21		43	21	24		45
Distant metastasis			0.062				0.501
Absent	34	40		74	39	37		76
Present	9	13		22	4	6		10
Tumor thrombus			0.826				0.110
No	25	26		51	32	25		57
Yes	18	17		35	11	18		29
Microvascular cancer thrombus			0.041				0.190
No	29	37		66	15	21		36
Yes	14	6		20	28	22		50
Early recurrence (≤12 months)			0.235				0.021
No	28	33		61	34	24		68
Yes	15	10		25	9	19		18

miR: microRNA; AFP: alpha-fetoprotein; BCLC stage: Barcelona Clinic Liver Cancer stage.